Please ensure Javascript is enabled for purposes of website accessibility

Here's Why ArQule Stock Rose as Much as 16.8% Today

By Maxx Chatsko - May 25, 2018 at 2:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma's incredible 2018 surge continues, but today's news is a little less exciting for investors.

What happened

Shares of development-stage biopharma ArQule (ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. 

It's a fairly standard move, but investors are taking it as a sign of maturation for the tiny biopharma company focused on developing treatments for cancer and rare diseases. Although it has accomplished relatively little in its nearly 20 years as a publicly traded company, recent developments have pushed ArQule stock up over 200% in 2018 alone.

As of 3:22 p.m. EDT, the stock had settled to a 12.8% gain.

Multiple lines with a positive slope drawn on a chalkboard.

Image source: Getty Images.

So what

ArQule has made quite a bit of noise in the last year after licensing rights to its leading drug candidate, derazantinib, to Basilea Pharmaceutica. The $800 million Swiss biopharma will be able to develop the drug candidate in most worldwide jurisdictions. It's currently enrolling a phase 3 trial as a potential treatment for intrahepatic cholangiocarcinoma (iCCA), the second-most common type of liver cancer. 

That move provided ArQule $10 million up front and the potential for up to $326 million in development and commercialization milestones. On top of that, the tinier company would be entitled to single-digit and double-digit tiered royalties on commercial sales.

There's no guarantee derazantinib will gain regulatory approval, but if it does, then ArQule could fund the development of the four other early-stage drug candidates in its pipeline. The bold bet to sell its lead drug candidate today for even bigger potential rewards in the future has been the driving force behind the stock's epic rise in the last six months.

Now what

Today's news of creating two new management positions isn't really that exciting or important for investors. But it did have the effect of keeping ArQule in the news, which, given the incredible rise in the stock price year to date, only added oxygen to the situation. While monetizing derazantinib could pay off over time, there's still a long way to go before this company proves it's worth anything close to its $500 million market cap. In other words, I wouldn't be surprised if this stock comes back to Earth before too long.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ArQule, Inc. Stock Quote
ArQule, Inc.
ARQL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.